Navigation Links
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Date:8/19/2009

n early significant reduction in distant metastases versus tamoxifen at a median follow-up of 26, 51 and 76 months.

"Femara is the only aromatase inhibitor to demonstrate consistent, early and significant reduction in risk of distant metastases," said Alessandro Riva, MD, Global Head Oncology Development, Novartis Oncology. "Based on these results, starting with Femara monotherapy for five years in the adjuvant setting instead of tamoxifen may offer breast cancer patients the opportunity for a better outcome."

Study details

This Phase III, randomized, double-blind, controlled clinical trial enrolled more than 8,000 postmenopausal women with early breast cancer in 27 countries[2].

Patients were randomly assigned one of four treatment regimens: (1) five years of tamoxifen only; (2) five years of Femara only; (3) two years of tamoxifen followed by three years of Femara; (4) two years of Femara followed by three years of tamoxifen.

The primary endpoint of the study was disease-free survival, defined as the time from randomization to the first of any of the following events: recurrence at local, regional, or distant sites; a new invasive cancer in the contralateral breast; any second, non-breast cancer; or death without a previous cancer event. Other endpoints included time to breast cancer recurrence, time to distant breast cancer recurrence and overall survival.

In 2005, following initial results showing superiority of Femara monotherapy over tamoxifen monotherapy in improving disease-free survival and reducing the risk of recurrence, the tamoxifen-only treatment arm was unblinded and approximately one quarter of those patients selectively crossed over to Femara treatment. The other three treatment arms remained blinded. Subsequent analyses were designed to estimate the extent to which the crossover affected the comparative benefit of Femara.


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)... special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 ... highlighting the success of the prescription drug benefit, commonly referred to as Part D. ... and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... Calif. , June 16 SanBio Inc. ( www.san-bio.com ) ... approved the clinical testing of their SB623 regenerative medicine product in patients ... marrow stromal cells (MSCs) isolated from healthy adult donors. , ... This Phase 1/2a clinical trial will test ...
... June 16 Trius Therapeutics, Inc. announced today ... and Drug Administration (FDA), under the Special Protocol Assessment (SPA) ... for the oral dosage form of torezolid phosphate for treatment ... double-blind pivotal study will compare the efficacy and safety of ...
Cached Medicine Technology:SanBio Receives FDA Clearance to Initiate Cell Therapy Clinical Studies for Stroke Recovery 2Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate 2
(Date:7/31/2015)... New York, New York (PRWEB) , ... ... ... Nationally renowned trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence ... from July 28th, 2015 was well received with a 94% approval rating ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their company mission, ... support of animal welfare organizations is essential to the longevity of their business. ... the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply drive. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Transfinder, a software company ... Total sales were up 16 percent year-over-year for the first six months ended June ... said he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. , ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, hosted by ... and 6. The event attracts over 250 “C”-level executives, administrators, directors of ...
(Date:7/31/2015)... ... 2015 , ... Mullin/Ashley Associates , a Mid-Atlantic branding, ... Awards national competition for a marketing communications campaign created for Atlantic General ... Coastal Maryland and Southern Delaware. , A Bronze Award was won for the ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
... stem cell researchers and other medical professionals from throughout ... in the heart of California,s Central Coast horse region ... cell therapy and regenerative medicine to treat horses and ... Conference will be held at the Santa Ynez Valley ...
... ... has added a new limited partner to its first venture fund, bolstering the fund’s ... , ... 2010 -- Mission Bay Capital, LLC, has added a new limited partner to its ...
... ... Book Will Make You Money” to give the keynote speech at the Affiliate Summit 2010 ... (PRWEB) ... Affiliate Summit event to learn and network about how to create and promote a successful ...
... ... suggest some health plans have used rescission to invalidate insurance policies for pre-existing ... consumers seeking to appeal their insurer’s decision to rescind their healthcare insurance have ... ...
... , ... Xserve Virtualization Offerings Capabilities for Businesses and Cloud Services Providers. , ... Renton, WA (PRWEB) February 24, 2010 ... announced that it is extending its server virtualization offerings for Apple environments with the ...
... ... small business. , ... (PRWEB) February 24, 2010 -- Verndale, a leading mid-market web technology and consultancy firm ... business, which is redefining the way websites are designed and managed. With Jumpstart, clients ...
Cached Medicine News:Health News:Horse stem cell conference to draw veterinarians and human-health professionals 2Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 2Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 3Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 4Health News:Online Business Marketing Consultant Jim Kukral Chosen To Keynote Affiliate Summit 2010 2Health News:Online Business Marketing Consultant Jim Kukral Chosen To Keynote Affiliate Summit 2010 3Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 2Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 3Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 4Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 2Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 3Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 4Health News:Verndale Announces the Release of Jumpstart 2Health News:Verndale Announces the Release of Jumpstart 3
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Mini Aprons are half aprons with an easy-on, easy-off Velcro-style closure that fastens securely in seconds. Color-coded sizes for easy identification. Offers 0.5 mm Pb equivalent protection....
... the first in portability and performance. CTU is ... a flexible, portable system with the state-of-the-art features of ... to an "E" size tank and has an optional ... it is needed.,The CTU Travel Case allows you to ...
Pilot and control your analysis at a touch. 26 parameters CBC/DIFF with autoloader...
Medicine Products: